

# Membrane-Localized Mutations Predict the Efficacy of Cancer Immunotherapy

Priscilla S. Briquez<sup>1+</sup>, Sylvie Hauer<sup>1\*</sup>, Zoe Goldberger<sup>1,2\*</sup>, Trevin Kurtanich<sup>1</sup>, Aaron T. Alpar<sup>1</sup>, Grégoire Repond<sup>1</sup>, Yue Wang<sup>1</sup>, Suzana Gomes<sup>1</sup>, Prabha Siddarth<sup>3</sup>, Melody A. Swartz<sup>1,4,5,6</sup>, Jeffrey A. Hubbell<sup>1,5,6+</sup>

\* These authors contributed equally to this work

+ Correspondence: [jhubbell@uchicago.edu](mailto:jhubbell@uchicago.edu), [pbriquez@uchicago.edu](mailto:pbriquez@uchicago.edu)

## Affiliations:

<sup>1</sup> Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA

<sup>2</sup> Department of Bioengineering, McGill University, Montreal, QC, Canada

<sup>3</sup> Semel Institute for Neuroscience & Human Behavior, UCLA, Los Angeles, CA, USA

<sup>4</sup> Ben May Department of Cancer Research, University of Chicago, Chicago, IL, USA

<sup>5</sup> Committee on Immunology, University of Chicago, Chicago, IL, USA

<sup>6</sup> Committee on Cancer Biology, University of Chicago, Chicago, IL, USA

## ABSTRACT

Due to their genetic instability, tumor cells bear mutations that can effectively be recognized by the immune system. In the clinic, immune checkpoint immunotherapy (ICI) can re-activate immune reactions against mutated proteins, known as neoantigens, leading to remarkable remission in cancer patients. Nevertheless, only a minority of patients are responsive to ICI, and approaches for prediction of responsiveness remain elusive yet are needed to improve the success of cancer treatments. While the tumor mutational burden (TMB) correlates positively with responsiveness and survival of patients undergoing ICI therapy, the influence of the subcellular localizations of the mutated proteins within the tumor cell has not been elucidated. Here, we hypothesized that the immune reactions are modulated by the localization of the mutated proteins and, therefore, that some subcellular localizations could favor responsiveness to ICI. We show in both a mouse melanoma model and human clinical datasets of 1722 ICI-treated patients that high membrane-localized tumor mutational burden (mTMB), particularly at the plasma membrane, correlate with responsiveness to ICI therapy and improved overall survival across multiple cancer types. We further highlight that mutations in the genes encoding for the membrane proteins *NOTCH3*, *RNF43*, *NTRK3* and *NOTCH1*, among others, may serve as potent biomarkers to predict extended survival upon ICI in certain cancer types. We anticipate that our results will improve the predictability of cancer patient response to ICI and therefore may have important implications to establish future clinical guidelines to direct the choice of treatment toward ICI.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 44 INTRODUCTION

45

46 Immunotherapies have revolutionized the landscape of clinical oncology, being  
47 established as first-line treatments in multiple advanced cancer types, including  
48 melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma<sup>1-3</sup>. Despite  
49 the strong efficacy of immune checkpoint immunotherapy (ICI), less than 20% of  
50 patients show complete or durable response<sup>4,5</sup>. While studies have shown that  
51 infiltration of immune cells in the tumors<sup>6</sup> and high tumor mutational burden (TMB)  
52 are key correlates of response to ICI<sup>7-12</sup>, accurate prediction of patient  
53 responsiveness to ICI remains an important challenge<sup>13</sup>. Greater predictivity certainly  
54 would increase patient survival and quality of life, by reducing the number, duration,  
55 and side-effects of treatments as well as associated economic burden.

56 Here, we hypothesized that the potency of immune response against tumor mutated  
57 proteins not only depends on the total mutational burden, but also on the subcellular  
58 localization of these proteins within the tumor cell. Indeed, the efficiency of  
59 presentation of mutated proteins on the major histocompatibility complex (MHC)-I by  
60 the tumor cell, required for recognition and killing by CD8<sup>+</sup> T cells<sup>14</sup>, might vary for  
61 cytoplasmic, nuclear, membrane-localized or secreted proteins due to their specific  
62 intracellular processing and trafficking routes<sup>15-17</sup>. In addition, efficiency in collection  
63 and presentation of these mutated proteins by antigen-presenting cells (APCs), on  
64 both MHC-I and -II to generate CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses, respectively, could  
65 similarly be impacted by these different forms of proteins upon release in debris,  
66 vesicles or in the extracellular milieu. Apart from antigen presentation, membrane-  
67 bound mutated proteins can be recognized by antibodies, induced via B cell  
68 immunity, which could allow antibody-dependent cytotoxic mechanisms that kill tumor  
69 cells by activating natural killer (NK) cells, macrophages or the immune complement  
70 cascade<sup>18,19</sup>. Of note, tumor mutated proteins that successfully activate an adaptative

71 immune response are commonly defined as tumor neoantigens.

72 To date, very few reports have examined how the subcellular localization of tumor  
73 mutated proteins modulates anti-cancer immunity. In this study, we show that high  
74 membrane-localized tumor mutational burden (mTMB) increase tumor  
75 immunogenicity and improve responsiveness to ICI therapies. We first demonstrated  
76 in a mouse model of melanoma that membrane-localization of OVA (mOVA; used  
77 here as a model tumor antigen) in B16-F10 cells increased local and systemic  
78 immunity as compared to soluble OVA and rendered these tumors highly susceptible  
79 to ICI, in a manner that did not depend on immunoglobulin G (IgG) antibody-  
80 mediated cytotoxicity. We then questioned if a high mTMB improves responsiveness  
81 to ICI in cancer patients. We developed a simple algorithm that extracts the  
82 subcellular localizations associated with tumor mutated genes from the  
83 UniprotKB/Swiss-Prot database<sup>20</sup> and analyzed the publicly available sequencing  
84 data of 4864 patients, treated or not with ICI, from studies by Samstein *et al.*<sup>7</sup>,  
85 Hellman *et al.*<sup>8</sup> and Hugo *et al.*<sup>9</sup>. We demonstrated that high mTMB correlates with  
86 increased patient survival and responsiveness to ICI across multiple cancer types.  
87 Moreover, we highlighted that mutated genes encoding for some particular  
88 membrane-localized proteins may serve as potent biomarkers to predict extended  
89 survival of patients upon ICI, such as *NOTCH1*, *NOTCH3*, *RNF43* or *NTRK3*.  
90 Together, our results highlight the importance of considering the subcellular  
91 localization of tumor mutated proteins, in particular mTMB, in addition to the total  
92 TMB, to improve the predictivity of patient responsiveness to ICI therapy and  
93 potentially the clinical guidelines for the selection of the most appropriate cancer  
94 treatment. Such findings may also have strong implications on vaccinal antigen  
95 selection for neoantigen-targeted cancer vaccines based on tumor gene sequencing.

96

## 97 RESULTS


98

### 99 Membrane-bound antigens increase tumor immunogenicity

100 We began by studying the effect of cell membrane-bound antigens in the B16-F10  
101 murine melanoma model. We first modified B16-F10 cells for expression of  
102 membrane-bound OVA (B16mOVA), by fusing the full-length OVA sequence to the  
103 transmembrane domain of H-2D<sup>B</sup> (Fig. S1a)<sup>21</sup>. As a control, we used B16-F10 cells  
104 that expresses full-length OVA in a soluble form (i.e., not membrane-bound; B16-  
105 OVA). For both designs, we generated cell lines with matching high (<sup>HI</sup>) and low (<sup>LO</sup>)  
106 levels of OVA expression, as quantified by qPCR (Fig. S1b, c). The presence of OVA  
107 at the surface of the B16mOVA cells, but not on the B16-OVA cells, was confirmed  
108 by flow cytometry and fluorescence (Fig. S1d, e). We further highlighted that  
109 membrane-bound OVA was secreted on extracellular vesicles produced by  
110 B16mOVA (Fig. S1f), which is potentially important to increase antigen transport and  
111 availability to APCs.

112 Upon intradermal injection in C57BL6 wild-type (WT) mice, all cell lines were  
113 tumorigenic. We observed that B16mOVA<sup>HI</sup> tumors grew significantly slower than  
114 B16-OVA<sup>HI</sup> and the parental B16 WT, which resulted in extended survival of mice  
115 bearing B16mOVA<sup>HI</sup> tumors (Fig. 1a, Fig. S1g). This effect was antigen dose-  
116 dependent, as seen by an intermediate growth rate of the B16mOVA<sup>LO</sup> tumors. To  
117 confirm that this difference was due to immune-mediated rejection of the tumor,  
118 rather than to a difference in cell growth/division rate, we evaluated B16mOVA<sup>HI</sup>  
119 tumor growth in transgenic Act-mOVA mice, which are immune tolerant to mOVA. In  
120 these mice, B16mOVA<sup>HI</sup> tumors grew faster than the B16 WT tumors, demonstrating  
121 an intact proliferation capacity of the B16mOVA<sup>HI</sup> cells (Fig. S1h). This supports the  
122 hypothesis that the slowed tumor growth in WT mice was due to an immune reaction  
123 against mOVA.

124 **Figure 1.**



125 **Figure 1. Membrane-bound antigens enhance melanoma tumor immunogenicity and**  
 126 **responsiveness to ICI in mice.** B16-F10 melanoma cells (1.5 M) modified to express  
 127 membrane-bound or soluble full-length ovalbumin (B16mOVA and B16-OVA, respectively), at  
 128 high (<sup>HI</sup>) or low (<sup>LO</sup>) levels, were injected intradermally in C57BL6 mice. The parental B16-F10  
 129 wild-type (WT) cells were used as a control. Where indicated, treatment with 200  $\mu$ g of anti-  
 130 PD-1 injected intraperitoneally was given to mice when their tumor volume reached 20-  
 131 50 mm<sup>3</sup> (grey thresholds). **a**, Tumor growth of the different OVA-expressing B16 cell lines  
 132 upon injection *in vivo* (N $\geq$ 8, mean  $\pm$  SEM, Kruskal-Wallis with Dunn's post-test at day 12).  
 133 **b**, Immune cell populations infiltrated in the different tumors at day 10 post-injection analysed  
 134 by flow cytometry (N $\geq$ 4, mean  $\pm$  SD, ANOVA with Tukey's post-test and Brown-Forsythe  
 135 correction when needed). **c**, *Ex vivo* restimulation of OVA-specific CD8<sup>+</sup> and CD4<sup>+</sup> T cells in  
 136 spleen of mice bearing the different OVA-expressing tumors at day 10 post-injection (N $\geq$ 4,  
 137 mean  $\pm$  SD, Kruskal-Wallis with Dunn's post-test). **d**, Anti-OVA antibody quantification per IgG  
 138 subtype in the plasma of tumor-bearing mice at day 10 post-injection (AUC: area under the  
 139 curve; N $\geq$ 4, mean  $\pm$  SD, Kruskal-Wallis with Dunn's post-test). **e**, Tumor growth and  
 140 associated survival of OVA-expressing tumor-bearing mice treated with anti-PD-1 (N $\geq$ 5, mean  
 141

142 ± SEM, log-rank tests with Holm-Bonferroni p-values adjustment). **f**, B16mOVA<sup>HI</sup> tumor  
143 growth upon depletion of CD8<sup>+</sup> or/and CD4<sup>+</sup> T cells with anti-PD1 treatment (N≥5, mean ±  
144 SEM, Kruskal-Wallis with Dunn's post-test at day 14). **g**, B16mOVA<sup>HI</sup> tumor growth upon  
145 depletion of NK1.1<sup>+</sup> or/and CD8<sup>+</sup> T cells with treatment with anti-PD1 (N≥5, mean ± SEM,  
146 Kruskal-Wallis with Dunn's post-test at day 20). **h**, B16mOVA<sup>HI</sup> tumor growth in MuMt mice  
147 (lacking mature B cells) with treatment with anti-PD-1 (N≥4, mean ± SEM, Kruskal-Wallis with  
148 Dunn's post-test at day 17). **i**, Tumor growth of mice that survived B16mOVA<sup>HI</sup> tumors treated  
149 with anti-PD-1 upon rechallenge with 250k B16-F10 WT cells (N≥8, mean ± SEM, Mann-  
150 Whitney test at day 14).

151

152 Therefore, we analyzed immune cell infiltrates in the different OVA-expressing B16-  
153 F10 tumors, reasoning that increased OVA-mediated tumor rejection would enhance  
154 the local presence of inflammatory cells (Fig. S2, S3). Indeed, we found a significant  
155 increase of CD45<sup>+</sup> immune cells in tumors that expressed mOVA as compared to  
156 dose-matched soluble OVA, of about 2-fold in the case of B16mOVA<sup>HI</sup> vs. B16-OVA<sup>HI</sup>  
157 tumors (Fig. 1b). Particularly, CD8<sup>+</sup> T cells and NK cells were more numerous in this  
158 tumor, but not CD4<sup>+</sup> T cells (Fig. 1b, Fig. S4a-c). No difference in PD-1 expression  
159 was observed on the T cells in the tumors expressing mOVA versus soluble OVA  
160 (Fig. S4d). Among the other immune cell types screened, NKT cells were slightly  
161 increased, and dendritic cells and B cells slightly decreased in the B16mOVA tumors  
162 when quantified relative to the total CD45<sup>+</sup> immune cell population (Fig. S4e).

163 Next, we assessed whether immunity against OVA in the B16mOVA-bearing mice  
164 was sufficiently strong to induce systemic immunity, in addition to local intratumoral  
165 inflammation. *Ex vivo* restimulation of splenocytes using OVA-derived MHC-I and  
166 MHC-II peptides revealed that both CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses were increased  
167 in mice with tumor expressing mOVA as compared to those with soluble OVA, as  
168 highlighted by the production of the pro-inflammatory cytokine interferon (IFN)- $\gamma$   
169 (Fig. 1c). In addition, OVA-specific antibody responses were detected in the plasma  
170 of tumor-bearing mice for both B16mOVA and B16-OVA, but different subtypes of  
171 immunoglobulin G (IgG) were generated, depending on the antigen localization.

172 Particularly, OVA-specific IgG2b and IgG2c were detected in mice bearing  
173 B16mOVA tumors but were largely absent in those bearing B16-OVA tumors  
174 (Fig. 1d, Fig. S4f).

175 Together, these results showed that membrane-bound tumor antigens, here  
176 modelled by mOVA, strongly enhanced tumor immunogenicity both locally and  
177 systemically, resulting in slowed tumor growth and extended survival of untreated  
178 mice.

179

### 180 **Membrane-bound antigens restore responsiveness to ICI**

181 While B16-F10 WT melanoma does not respond ICI, we examined whether the  
182 increased immunogenicity of the B16mOVA, particularly the enhanced presence of  
183 intratumoral T cells, would render them more susceptible. Remarkably, all mice  
184 (5 out of 5) bearing B16mOVA<sup>HI</sup> tumors and treated with anti-PD1 therapy showed  
185 complete responses to ICI, whereas B16-OVA<sup>HI</sup> and B16 WT-bearing mice were  
186 completely unresponsive (Fig. 1e). Lowering the antigen dose in the B16mOVA<sup>LO</sup>  
187 group reduced the efficacy of ICI yet resulted in 2 out of 5 tumor eradications and  
188 otherwise slowed tumor growth. Such effects were also confirmed using the  
189 combination therapy anti-PD-L1 and anti-CTLA-4 (Fig. S4g). In both therapies,  
190 responsiveness to ICI significantly extended survival.

191 We then characterized which cell types were predominantly involved in the  
192 B16mOVA<sup>HI</sup> tumor rejection by depleting specific immune cells populations upon ICI  
193 treatment. In the absence of the CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells were still capable of  
194 controlling tumor growth and led to the rejection in 3 out of 5 mice, thus with slightly  
195 lower efficacy than with proper help from the CD4<sup>+</sup> T cells, as highlighted by the  
196 isotype control group in which all tumors were rejected (Fig. 1f). In contrast, CD4<sup>+</sup> T  
197 cells alone were insufficient to eradicate tumors, although they slightly slowed tumor



198 growth as compared to tumors depleted of both CD8<sup>+</sup> and CD4<sup>+</sup> T cells. Similarly, we  
199 found that NK1.1<sup>+</sup> cells were not required for responsiveness to ICI (Fig. 1g). Lastly,  
200 we found that muMT<sup>-</sup> transgenic mice, which lack mature B cells and cannot produce  
201 IgG, were able to reject B16mOVA<sup>H1</sup> tumors upon ICI, importantly highlighting that  
202 IgG-based antibody-dependent cytotoxicity mechanisms were not necessary for  
203 tumor eradication, although we do not exclude that they might take place in WT mice  
204 (Fig. 1h).

205 Finally, we investigated whether the immune rejection of the B16mOVA tumors upon  
206 ICI was solely directed against membrane-bound OVA or if immune reactions against  
207 other tumor-associated antigens were at play. Upon re-challenge, mice that rejected  
208 B16mOVA tumors showed delayed growth of B16 WT tumors, suggesting the  
209 presence of pre-existing immune reactions against B16 WT neoantigens induced  
210 during the initial rejection of B16mOVA (Fig. 1i, Fig. 4h). Of note, the secondary B16  
211 WT tumors remained non-responsive to ICI. Therefore, while mOVA was necessary  
212 to eradicate the primary tumor upon ICI, its loss in the secondary tumors still resulted  
213 in delayed tumor growth, potentially mimicking a situation of cancer relapse or  
214 metastasis.

215

## 216 **mTMB increase patient survival upon ICI**


217 The remarkable ability of a membrane-bound antigen (i.e., mOVA) to restore  
218 responsiveness to ICI in the murine melanoma model encouraged us to validate this  
219 hypothesis in cancer patients. Therefore, we analyzed publicly available tumor  
220 mutation sequencing data of patients treated or not with ICI, from 3 independent  
221 studies by Samstein *et al.*<sup>7</sup>, Hellman *et al.*<sup>8</sup> and Hugo *et al.*<sup>9</sup>. For each tumor mutated  
222 gene detected in patients, we extracted the subcellular localization of its encoded  
223 protein from the UniProtKB/Swiss-Prot database<sup>20</sup> (Supplementary Data 1). We then



224 quantified per patient the number of mutated genes that encode for membrane,  
225 cytoplasmic, nuclear, or secreted proteins. Genes that encode proteins expressed at  
226 several localizations were classified in all locations, in a non-exclusive manner. We  
227 lastly normalized the number of protein-encoding mutated genes at a specific  
228 subcellular location to the total number of mutated genes, therefore obtaining  
229 proportions of protein-encoding mutated genes per subcellular location (Fig. 2a).  
230 These proportions are here called mTMB, cTMB, nTMB or sTMB for membrane,  
231 cytoplasmic, nuclear, or secreted -localized TMB, respectively.

232 We first analyzed the dataset by Samstein et al.<sup>7</sup> comprising of 1609 patients with  
233 9 different types of advanced cancers treated with ICI whose tumor mutations were  
234 determined using targeted next-generation sequencing MSK-IMPACT  
235 (Supplementary Data 2). In total, 424 genes out of the 469 sequenced were  
236 classified in the 4 subcellular locations of interest (Fig. S5a). We compared groups of  
237 patients with high and low proportion of mutated genes for each specific location  
238 using the cutoff values of the upper and bottom group quartiles (Top 25% vs. Bottom  
239 25%; Fig. S5b). A high mTMB was found to correlate with significantly increased  
240 patient survival (Fig. 2b). This effect also was conserved at other percentiles than  
241 25% (Fig. S5c). Interestingly, an insufficient mTMB was strongly associated with  
242 worsened survival, as highlighted by the gradual decrease between the groups  
243 Bottom 50%, 25% and 10%, with the Bottom 10% group being patients with no  
244 membrane-localized mutation (Fig. 2b, Fig. S5d). None of the other subcellular  
245 locations correlated with significant improvement in survival (Fig. 2c). Instead, trends  
246 toward reduced survival were observed for high cTMB and nTMB, and no difference  
247 was seen for sTMB. Further division into exclusive patient groups with high  
248 proportions of mutated genes at a single location highlighted that the membrane  
249 localization provides higher survival benefits than the cytoplasmic and nuclear  
250 localizations (Fig. 2d, Fig. S5e).

251 **Figure 2.**



252  
253

**Figure 2. mTMB correlates with an increased survival in cancer patients treated with ICI**

254

**in a pan-cancer analysis.** Data available from Samstein *et al.*<sup>7</sup>. Patients suffering from 9

255

different cancer types were treated with immune checkpoint inhibitor (ICI) immunotherapy,

256

and their survival was evaluated from the first day of treatment (N=1609 patients). A control

257

cohort of patients non-treated with immunotherapy was used for comparison (N=3142

258

patients). All Kaplan-Meier survival curves and Cox hazard ratios (HR) for survival were

259

statistically compared using log-rank tests. **a**, Graphical representation of the workflow for the

260

analysis of subcellular localizations associated with the tumor mutations. **b**, Survival of

261

patients with high (Top 25% group) or low (Bottom 50%, 25% or 10% groups) mTMB.

262

**c**, Survival curves of patients having high (Top 25% group) or low (Bottom 25% group) cTMB,

263

nTMB or sTMB. **d**, Survival of patients as a function of their predominant subcellular location

264

of mutated genes (Top 25% groups of membrane, nucleus or cytoplasm mutations; p-values

265

adjusted using Holm-Bonferroni correction). **e**, Survival of non-ICI-treated patients that have

266

high (Top 25%) or low (Bottom 25%) mTMB. **f**, HR for survival of patients having high (Top

267

25%) versus low (Bottom 25%) mTMB upon ICI treatment, non-treated with immunotherapy

268

(Non-ICI), or depending on the type of ICI received, i.e. PD-1/PDL-1, CTLA-4 or in

269

combination (HR ± 95% CI).

270

271 We then questioned whether the survival advantage that correlated with high mTMB  
272 was present in non-ICI treated patients. We analyzed 3142 patients from the non-ICI  
273 treated control cohort of Samstein *et al.*<sup>7,22</sup> (Supplementary Data 3) and found that no  
274 survival benefit was associated with membrane localization in absence of ICI  
275 (Fig. 2e, f). However, all types of ICI therapies, namely PD-1/PD-L1, CTLA-4 or the  
276 combination PD-1/PD-L1 + CTLA-4, correlated with extended survival in patients  
277 harboring a high mTMB, as indicated by a hazard ratio (HR) for survival inferior to 1.  
278 This effect did not reach statistical significance for CTLA-4, likely due to the limited  
279 number of patients in this group (Fig. 2f).

280 Together, these findings suggest that high mTMB improve cancer patient survival  
281 upon different types of ICI treatments.

282

### 283 **Impact of mTMB in different cancer types**


284 The ICI-treated cohort analyzed above included patients with 9 different types of  
285 cancers, non-equally distributed (Fig. S6a). When comparing the distribution of  
286 cancer types within the Top 25% and Bottom 25% of mTMB groups, we noticed that  
287 the population with high mTMB was enriched in melanoma, renal cell carcinoma and  
288 colorectal cancer patients, and depleted from bladder cancer, glioma and head-and-  
289 neck cancer patients (Fig. S6b). This implied that not all cancer types had the same  
290 distribution of mTMB; in fact, glioma, bladder and head-and-neck cancers had  
291 significantly less mTMB than the pan-cancer group, whereas colorectal and  
292 melanoma cancers had significantly more (Fig. 3a).

293

294

295

296 **Figure 3.**



297

298 **Figure 3. mTMB correlates with increased survival in multiple cancer types.**

299 **a**, Distribution of mTMB by cancer types (blue line: cutoff value (CV) for the pan-cancer upper  
300 quartile, red line: cutoff value for the pan-cancer lower quartile; Kruskal-Wallis test with  
301 Dunn's post-tests for comparisons to the pan-cancer group). **b**, Heatmap of the HR for  
302 survival of patients harboring high versus low mutational load per subcellular location and per  
303 cancer types. High and low groups are determined using either the cutoff values (CV) from  
304 the pan-cancer group or the upper and lower quartiles (25%) specific to each cancer type  
305 (log-rank tests).

306

307 Therefore, we detailed the effects of high mTMB, as well as of other subcellular  
308 localizations, per cancer type. We computed the HR for survival to compare patients  
309 with high versus low proportions of mutated genes at a specific location, using 2  
310 different strategies: 1) keeping the same cutoff values that we used for the pan-  
311 cancer group analysis in Fig. 2, reasoning that a "universal" threshold might be  
312 determined across cancers as being an absolute proportion of mutations required for  
313 extended survival, or 2) using the upper and lower quartile values specific to each  
314 cancer type (Fig. 3b, Fig. S6c). Overall, a high mTMB correlates with better survival  
315 in 6 out of 9 individual cancers, with statistical significance reached in the renal cell  
316 carcinoma and head-and-neck cancer, and close to significance for esophagogastric  
317 cancer. The lack of significance in the other cancer types might be due to smaller  
318 effects or limited numbers of patients in each sub-cohort. On the other hand, high  
319 cTMB and nTMB were associated with worsened survival in a majority of cancer

320 types (6 out of 9; 1 or 2 significantly). Besides, high sTMB did not strongly impact  
321 patient survival, except in the esophagogastric cancer, in which a trend toward  
322 improvement was observed. Interestingly, both thresholding methods for the  
323 selection of high vs. low groups showed very similar results, except for glioma and  
324 bladder cancers at the membrane locations. Further analysis with a higher number of  
325 patients would clarify whether an absolute threshold for mTMB can be determined to  
326 predict increased survival upon ICI across cancers.


327

### 328 **mTMB predict patient response to ICI**

329 While the metric of survival is a relevant measure to evaluate effectiveness of ICI,  
330 response rate and long-term survival do not always correlate well. Hence, we  
331 searched for published datasets in which the patient response to ICI was reported.  
332 We found 2 such studies, from Hellman *et al.*<sup>8</sup> and Hugo *et al.*<sup>9</sup>, which respectively  
333 focused on ICI-treated patients with NSCLC (75 patients) and metastatic melanoma  
334 (38 patients). Both studies used whole-exome sequencing (WES) to determine tumor  
335 mutations in patients treated with anti-PD-1 or with the combination of PD-1 and  
336 CTLA-4 blockade. We thus repeated the subcellular localization analysis using the  
337 same algorithm to categories tumor mutated genes according to their possible  
338 expression in the membrane, cytoplasm, nucleus or secreted category (Fig. S7a,  
339 Supplementary Data 4, 5). Because more genes were sequenced by WES than by  
340 MSK-IMPACT, the detected variation range of mTMB in the WES-sequenced  
341 patients was much smaller, with most patients having between 25-35% of mutated  
342 genes at the membrane location. Interestingly, the overall median mTMB remained  
343 similar between the studies, with 33.3%, 27.0% and 34.3% in Samstein *et al.*<sup>7</sup>,  
344 Hellman *et al.*<sup>8</sup> and Hugo *et al.*<sup>9</sup>, respectively (Fig. S7b). The small difference of  
345 lowered mTMB found in the cohort from Hellman *et al.*<sup>8</sup> might be due to the increased  
346 number of genes for which the subcellular locations could not be determined.

347 In this NSCLC cohort<sup>8</sup>, patients that responded to ICI had a significantly higher  
348 mTMB, but none of the other studied locations. In addition, these patients tended to  
349 survive longer, although statistical significance was not obtained, highlighting the  
350 potential discrepancy between ICI responsiveness and overall survival readouts (Fig.  
351 4a, Fig. S7c, d). Impressively, the response rate was 61% in the group with high  
352 mTMB (25% Top), vs. 23.5% in patients with low mTMB (25% Bottom) (Fig. 4b).  
353 Similar trends were also observed in the melanoma cohort, despite the low number  
354 of patients (Fig. S7e-g). Thus, these two additional studies further support the  
355 hypothesis that a high mTMB correlates with ICI responsiveness, consistently with  
356 the survival results obtained in the larger, multi-cancer cohort from Samstein *et al.*<sup>7</sup>.  
357 Importantly, they also point out that this effect was conserved independently of the  
358 sequencing methods used for the detection of the tumor mutations.

359 **Figure 4.**



360

361 **Figure 4. mTMB correlates with better responsiveness to cancer ICI.** Data available from  
 362 Hellman *et al.*<sup>8</sup>. Patients (N=75) with non-small cell lung cancer were treated with a  
 363 combination of anti-PD-1 and anti-CTLA-4 immunotherapy, and their responsiveness to  
 364 treatment was evaluated (responders: complete or partial response (CR/PR); non-  
 365 responders: stable disease or progressive disease (SD/PD)). **a**, mTMB in patients that  
 366 responded or not to the immunotherapy (Mann-Whitney test). **b**, Proportion of responders and  
 367 non-responders in patients with high (Top 25%) or low (Bottom 25%) mTMB (Fisher's exact  
 368 test). **c**, Proportion of mutated genes at the cell plasma membrane or in other specific  
 369 membrane-containing cell organelles in responders and non-responders to immunotherapy.  
 370 **d**, Heatmap of the HR for survival comparing the Top vs. Bottom 50%, 25% or 10% groups  
 371 having mutations at the plasma membrane or in other membrane-containing organelles,  
 372 from the cohorts from Samstein *et al.*<sup>7</sup> (pan-cancer group), Hellman *et al.*<sup>8</sup> and Hugo *et al.*<sup>9</sup>.



### 373 **mTMB at the plasma membrane**

374

375 Observing that mTMB lead to greater response to ICI, we questioned whether there  
376 were differences between particular membranes in the cell. To address this, we  
377 refined our algorithm to segregate for cell membrane (i.e., plasma membrane),  
378 endoplasmic reticulum, Golgi apparatus or endosome localizations. Using the data  
379 on ICI responders from the NSCLC cohort<sup>8</sup>, we found that only the proportion of  
380 mutated genes expressing proteins at the cell plasma membrane was significantly  
381 increased in ICI responders, while localization at the membranes of organelles did  
382 not correlate with changes in ICI response (Fig. 4c). Similar trends were observed for  
383 the melanoma cohort (Fig. S7h). In addition, consistent trends toward improvement  
384 of survival for patient with increased cell plasma-localized mTMB was observed  
385 across the pan-cancer, NSCLC and melanoma cohorts (Fig. 4d, Fig. S7i).

386

### 387 **Membrane-localized mutations as clinical biomarkers for ICI**

388 Finally, we analyzed which membrane protein-encoding mutated genes most impact  
389 survival upon ICI. Using the dataset from Samstein *et al.*<sup>7</sup>, we computed the HR of  
390 survival between patients bearing mutated and wild-type membrane protein-encoding  
391 genes, within each cancer type (Fig. 5a, Supplementary Data 6). We observed that  
392 most of the mutated genes correlated with improved survival, although a few of them  
393 correlated with worsened survival. We particularly highlighted a subset of 1-13 genes  
394 per cancer type for which mutations could serve as potent biomarkers to predict  
395 extended survival upon ICI, as indicated by low HRs (in blue in Fig. 5a and  
396 Supplementary Data 6). Interestingly, we found that patients bearing at least one of  
397 these biomarkers survived significantly longer than patients with none, in all the  
398 cancer types for which enough patients were available, i.e., bladder cancer,  
399 colorectal cancer, NSCLC, melanoma and renal cell (Fig. S8a). This represents a

400 substantial proportion of patients, between 28.4% and 74.1% depending on the  
401 cancer type, thus highlighting a strong potential for clinical translation of these  
402 membrane-localized biomarker sets.

403 Further seeking ICI-specific membrane-localized biomarkers, we compared the HRs  
404 obtained upon ICI to the ones from the non-ICI-treated cohort, for each gene for  
405 which enough patients were available (Fig. 5a, Supplementary Data 6). In most  
406 cases, gene mutations did not seem to improve survival in the non-ICI-treated cohort  
407 to the same extent than in the ICI-treated cohort, suggesting that these biomarkers  
408 could be specific for prediction of ICI efficacy. One exception was *VHL* in renal cell  
409 carcinoma, for which mutations appeared to be beneficial in both cohorts. On the  
410 other hand, we found that some mutated genes correlated with very high survival in  
411 the ICI-treated cohort, but with worsened survival in the non-ICI-treated one, such as  
412 *NOTCH3* or *RNF43* in colorectal cancer (the latter having been recently elucidated  
413 by Zhang et al.<sup>23</sup>), and *NTRK3* and *NOTCH1* in NSCLC (Fig. 5b, c, Fig. S8b, c).  
414 Upon confirmation by future studies, such genes could constitute very promising  
415 stand-alone biomarkers to guide medical choice toward ICI rather than other  
416 treatments in specific cancer types.


417 Among the membrane-localized biomarkers that we highlighted, a few are  
418 recognized by the U.S. Food and Drug Administration (FDA) as biomarkers predictive  
419 of response of a FDA-approved drugs<sup>24</sup> (Fig. 5d), and thus are currently assayed in  
420 the clinic. It is the case for some *BRAF* mutations in colorectal cancer, *MET* and *RET*  
421 mutations in NSCLC, or *NTRK2/3* mutations<sup>24</sup>. Therefore, we attempted to compare  
422 the performance of these membrane-localized biomarkers to predict survival upon ICI  
423 versus upon their clinically-associated treatments, using survival data from other  
424 published clinical studies by Kopetz et al.<sup>25</sup>, Paik et al.<sup>26</sup> and Gautschi et al.<sup>27</sup>. While  
425 such direct comparisons cannot be conclusive due to intrinsic differences in the study  
426 designs, *BRAF* and *RET* mutations seem highly effective as biomarkers for ICI as  
427 compared to the FDA-approved encoferanib+cetuximab in colorectal cancer<sup>25</sup>

428 (Fig. 5e) and tepotinib in NSCLC<sup>26</sup> (Fig. 5f), respectively. A similar observation was  
429 made for *RET* mutations, when compared to a standard-of-care treatment with  
430 cabozantinib in NSCLC<sup>27</sup> (Fig. S8d).

431 Last but not least, the FDA has very recently approved the use of high TMB (i.e.,  
432  $TMB \geq 10$  mutations/megabase pair (mut/Mbp)) as a criterion for ICI, for adults and  
433 children with unresectable or metastatic solid tumors that failed to respond to prior  
434 therapies<sup>28</sup>, thus fostering the use of next-generation sequencing of tumor mutations  
435 in the clinic. Because determination of the mTMB from these sequencing data would  
436 require only a simple algorithm but no additional clinical or laboratory procedures, we  
437 examined the benefit of combining mTMB analysis with the standard total TMB  
438 analysis to predict survival upon ICI. We found that a high mTMB correlated with  
439 improved survival in patients with both low TMB ( $< 10$  mut/Mbp) or high TMB  
440 ( $\geq 10$  mut/Mbp) (Fig. 5g, Fig. S8e, f). In addition, we observed that some patients with  
441 high TMB (10-20 mut/Mbp) but low mTMB, for which ICI is approved, had similar  
442 survival as patients with low TMB but high mTMB (Fig. 5h), which may not currently  
443 qualify for ICI. Importantly, the latter represent 30.5% of the patients in the Samstein  
444 *et al.* dataset, which could thus be considered for ICI but would not be otherwise.  
445 Together, this suggests that the mTMB could be a valuable parameter to take into  
446 account, on top of current TMB analysis, to extend the inclusion criteria for ICI in the  
447 clinic.

448

449 **Figure 5.**



450

451 **Figure 5. mTMB and specific membrane protein-encoding mutated genes as potent**  
 452 **biomarkers for ICI in the clinic.** The ICI- and non-ICI-treated cohorts from Samstein *et al.*<sup>7</sup>  
 453 were analyzed to determine which membrane protein-encoding mutated genes or  
 454 combination of them were the most potent to predict survival upon ICI. **a**, HR of survival  
 455 associated with specific membrane protein-encoding genes per cancer type. A HR < 1  
 456 indicates that the mutated version of the gene correlates with increased patient survival as  
 457 compared to the wild-type gene. The 1-13 membrane-associated top genes for favorable  
 458 prognosis are labelled in blue, whereas the ones for poor prognosis are in red, for the ICI-

459 treated cohort. Corresponding gene-specific HRs from the non-ICI treated cohort are in grey  
460 (log-rank test, \* $p < 0.05$ ). Patient coverage indicates the proportion of patient that contains at  
461 least one of the mutated genes in blue. **b**, Survival curves of ICI and non-ICI treated patients  
462 bearing *NOTCH3* mutations in colorectal cancer. **c**, Survival curves of ICI and non-ICI treated  
463 patients bearing *NTRK3* mutations in NSCLC. **d**, List of selected membrane protein-encoding  
464 genes that are currently recognized by the FDA as biomarkers predictive of a response to  
465 FDA approved drug according to the OncoKB database<sup>24</sup> (those recognized for use within the  
466 same cancer type as found in Fig. 5a are shown in blue). **e**, Comparison of survival of  
467 patients carrying *BRAF* mutations in colorectal cancer treated with ICI or with the FDA-  
468 approved encorafenib+cetuximab therapy (data from Kopetz *et al.*<sup>25</sup>). **f**, Comparison of  
469 survival of patients carrying *MET* mutations in NSCLC treated with ICI or with the FDA-  
470 approved tepotinib therapy (data from Paik *et al.*<sup>26</sup>). **g**, Comparison of survival of patients with  
471 high (> median) or low (< median) mTMB for different levels of TMB (TMB  $\geq 10$  mut/Mbp  
472 being the FDA-validated cutoff for ICI treatment for solid tumors<sup>28</sup>) in a pan-cancer analysis.  
473 **h**, Survival curves comparing patients with low TMB (< 10 mut/Mbp) and high mTMB to  
474 patients with high TMB (between 10-20 mut/Mbp) and low mTMB, in a pan-cancer analysis.  
475 No statistically significant difference was observed between the two groups (log-rank test).

476

477

478

## 479 **DISCUSSION**

480

481 This study focused on the influence of the subcellular localization of tumor mutations  
482 for responsiveness to cancer immunotherapy. Importantly, we demonstrated in both  
483 the B16-F10 melanoma mouse model and on a large clinical dataset of 4864 ICI- and  
484 non-ICI-treated cancer patients that responsiveness to ICI and extended survival  
485 correlated with a high mTMB, especially of mutations localized at the plasma  
486 membrane. Interestingly, this effect was not seen for increased load of cytoplasmic,  
487 nuclear, or secreted mutations, nor was it seen in patients that were not treated with  
488 ICI. This conclusion was supported in a pan-cancer analysis, gathering 9 different  
489 types of cancer. While pan-cancer analysis bears the limitation of merging possibly  
490 heterogeneous cancer types, it presents the strong advantage of including a large  
491 number of patients, therefore increasing statistical power, and mirrors the design of  
492 basket clinical trials currently emerging in oncology<sup>29,30</sup>. Further analyses per

493 individual cancer type similarly correlated high mTMB with extended survival in renal  
494 cell carcinoma and head and neck cancer in the cohorts from Samstein et al.<sup>7</sup>,  
495 although statistical significance depended on the thresholding methods, in a  
496 melanoma cohort from Hugo et al.<sup>9</sup>, and in an NSCLC cohort from Hellmann et al.<sup>8</sup>.  
497 Nevertheless, in-depth analysis per cancer type would be needed on larger number  
498 of patients to further elaborate on these conclusions, as we pointed out that high  
499 mTMB might have varying effects in different cancer types.

500 In our analysis, we found consistent results from clinical datasets published by three  
501 independent research groups, which used two different methods of tumor mutation  
502 sequencing, namely MSK-IMPACT and WES, both recently approved by the FDA  
503 and rapidly emerging in the clinic<sup>31-34</sup>. While these sequencing methods aim to  
504 quantify TMB, high load of which is approved as an inclusion criterion for treatment  
505 with ICI, our work provides a complementary simple algorithm-based method that  
506 can further filter the sequencing data to improve the prediction accuracy of ICI  
507 responsiveness. We found that our mTMB criterion indicates 30.5% more patients for  
508 inclusion into ICI than the current FDA standard of TMB, based on the Samstein et  
509 al. dataset<sup>7</sup>. In addition, we highlighted particular membrane proteins-encoding  
510 mutated genes that may be very potent stand-alone predictive biomarkers to guide  
511 the choice toward treatment by ICI in certain cancer types.

512 Although not formally demonstrated here, the membrane-localized proteins encoded  
513 by mutated genes constituting the mTMB are likely corresponding to membrane-  
514 localized tumor neoantigens. Additional analyses of expression of the mutated genes  
515 and prediction of mutated epitope binding on patient-specific MHC molecules would  
516 be required to support this assertion. That said, both Hugo et al.<sup>9</sup> and Hellmann et  
517 al.<sup>8</sup> successfully demonstrated that the total TMB, particularly the amount of somatic  
518 non-synonymous single-nucleotide variants (nsSNV), strongly correlates with HLA1

519 neoantigen load. As to the dataset from Samstein et al., HLA subtypes of patients  
520 were not found to be publicly available, to our knowledge, to permit such analysis.

521 The details of the mechanisms by which membrane-localized mutations modulate  
522 immune responses against cancer remain to be clarified. Our data in the B16-F10  
523 mouse model suggest that this effect strongly relies on T cells, rather than on NK  
524 cells or on IgG-dependent cytotoxic mechanisms. While CD8<sup>+</sup> T cells were necessary  
525 and sometimes sufficient to eradicate the tumors, our data supports that CD4<sup>+</sup> T cells  
526 provided important help to the CD8<sup>+</sup> T cells, consistent with other reports that  
527 stressed the key role MHC-II restricted neoantigens for responsiveness to ICI<sup>35</sup>. In  
528 addition, some previous research has highlighted that secreted<sup>36</sup>, membrane-bound<sup>37</sup>  
529 or extravesicular-bound<sup>38</sup> antigens enhance CD4<sup>+</sup> T cell responses and strengthen  
530 antigen-specific immunity, in cancer or other contexts. Considering that none of our  
531 data supported an immunogenic effect mediated by direct extracellular detection of  
532 unprocessed membrane-bound antigens, such as via IgG, we did not further focus on  
533 the precise effects of mutations' localization on cytoplasmic, transmembrane or  
534 extracellular domain of the mutated membrane proteins in this study. Lastly, apart  
535 from being immune targets, mutations of membrane proteins on tumor cells can  
536 impact the primary biological functions of the proteins and their downstream  
537 signaling, which could have direct effects on tumor biology, growth and  
538 aggressiveness.

539 Besides the basic immunology perspective, this work provides a rationale for  
540 therapeutic immunomodulation by neoantigen selection at different subcellular  
541 locations. In particular, personalized cancer vaccines currently target neoantigens  
542 based on prediction of MHC binding neopeptides for optimized T cell activation, with  
543 little consideration of the subcellular localization of the neoantigen<sup>13</sup>. Adding vaccinal  
544 antigen selection criteria for preferential targeting of plasma membrane neoantigens  
545 might improve the therapeutic efficacy of such vaccines. Taken together, we believe



546 that the simplicity of considering the neoantigens' subcellular localizations for  
547 increased predictability to ICI response, the use of mTMB and specific membrane  
548 neoantigens as biomarkers to guide medical decisions of cancer treatments, as well  
549 as the possible impacts on the design of future immunotherapies, will be valuable in  
550 the fight against cancer.

551

## 552 REFERENCES

553

- 554 1. Peters, S., Reck, M., Smit, E. F., Mok, T. & Hellmann, M. D. How to make the best use of  
555 immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer.  
556 *Annals of Oncology* **30**, 884–896 (2019).
- 557 2. Murciano-Goroff, Y. R., Warner, A. B. & Wolchok, J. D. The future of cancer immunotherapy:  
558 microenvironment- targeting combinations. *Cell Research* 1–13 (2020). doi:10.1038/s41422-  
559 020-0337-2
- 560 3. Vaddepally, R. K., Kharel, P., Pandey, R., Garje, R. & Chandra, A. B. Review of Indications of  
561 FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.  
562 *Cancers* **12**, 738 (2020).
- 563 4. Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. *Nature*  
564 *Communications* **11**, 3801–3 (2020).
- 565 5. Robert, C. *et al.* Durable Complete Response After Discontinuation of Pembrolizumab in  
566 Patients With Metastatic Melanoma. *J Clin Oncol* **36**, 1668–1674 (2018).
- 567 6. Depil, S. Cold Tumors: A Therapeutic Challenge for Immunotherapy. 1–10 (2019).  
568 doi:10.3389/fimmu.2019.00168
- 569 7. Samstein, R. M. *et al.* Tumor mutational load predicts survival after immunotherapy across  
570 multiple cancer types. *Nat Genet* **51**, 202–206 (2019).
- 571 8. Hellmann, M. D. *et al.* Genomic Features of Response to Combination Immunotherapy in  
572 Patients with Advanced Non-Small-Cell Lung Cancer. *Cancer Cell* **33**, 843–852.e4 (2018).
- 573 9. Hugo, W. *et al.* Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in  
574 Metastatic Melanoma. *Cell* **165**, 35–44 (2016).
- 575 10. Keenan, T. E., Burke, K. P. & Van Allen, E. M. Genomic correlates of response to immune  
576 checkpoint blockade. *Nat. Med.* 1–14 (2019). doi:10.1038/s41591-019-0382-x
- 577 11. Tran, E., Robbins, P. F. & Rosenberg, S. A. ‘Final common pathway’ of human cancer  
578 immunotherapy: targeting random somatic mutations. *Nat. Immunol.* **18**, 255–262 (2017).
- 579 12. Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D. & López-Soto, A. The hallmarks of  
580 successful anticancer immunotherapy. *Sci Transl Med* **10**, (2018).
- 581 13. Wells, D. K. *et al.* Key Parameters of Tumor Epitope Immunogenicity Revealed Through a  
582 Consortium Approach Improve Neoantigen Prediction. *Cell* **183**, 818–834.e13 (2020).
- 583 14. Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A. & Jaffee, E. M. Targeting neoantigens to  
584 augment antitumour immunity. *Nat Rev Cancer* **17**, 209–222 (2017).
- 585 15. Blum, J. S., Wearsch, P. A. & Cresswell, P. Pathways of antigen processing. *Annu. Rev.*  
586 *Immunol.* **31**, 443–473 (2013).
- 587 16. Neefjes, J., Jongasma, M. L. M., Paul, P. & Bakke, O. Towards a systems understanding of MHC  
588 class I and MHC class II antigen presentation. *Nat Rev Immunol* 1–14 (2011).  
589 doi:10.1038/nri3084
- 590 17. Vyas, J. M., Van der Veen, A. G. & Ploegh, H. L. The known unknowns of antigen processing  
591 and presentation. *Nat Rev Immunol* **8**, 607–618 (2008).
- 592 18. Briquez, P. S. *et al.* Engineering Targeting Materials for Therapeutic Cancer Vaccines. *Front*  
593 *Bioeng Biotechnol* **8**, 19 (2020).
- 594 19. Almagro, J. C., Daniels-Wells, T. R., Perez-Tapia, S. M. & Penichet, M. L. Progress and  
595 Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy. *Front.*  
596 *Immunol.* **8**, 495–19 (2018).
- 597 20. UniProt Consortium. UniProt: the universal protein knowledgebase in 2021. *Nucleic Acids Res.*  
598 **49**, D480–D489 (2021).
- 599 21. DiLillo, D. J., Yanaba, K. & Tedder, T. F. B cells are required for optimal CD4+ and CD8+ T cell  
600 tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. *The*  
601 *Journal of Immunology* **184**, 4006–4016 (2010).
- 602 22. Zehir, A. *et al.* Mutational landscape of metastatic cancer revealed from prospective clinical  
603 sequencing of 10,000 patients. *Nat. Med.* **23**, 703–713 (2017).
- 604 23. Zhang, N., Shi, X., Ju, W., Lou, Y. & Luo, X. Rnf43 Mutation As A Biomarker For Immune  
605 Checkpoint Inhibitor Efficacy In Colorectal Cancer. (2021). doi:10.21203/rs.3.rs-536739/v1
- 606 24. Chakravarty, D. *et al.* OncoKB: A Precision Oncology Knowledge Base. *JCO precision oncology*

- 607           **2017**, (2017).
- 608   25.   Kopetz, S. *et al.* Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal  
609   Cancer. *N Engl J Med* **381**, 1632–1643 (2019).
- 610   26.   Paik, P. K. *et al.* Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping  
611   Mutations. *N Engl J Med* **383**, 931–943 (2020).
- 612   27.   Gautschi, O. *et al.* Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From  
613   the Global, Multicenter RET Registry. *J Clin Oncol* **35**, 1403–1410 (2017).
- 614   28.   U.S. Food and Drug Administration. FDA approves pembrolizumab for adults and children with  
615   TMB-H solid tumors. 1–3 (2021). Available at: (Accessed: 5 July 2021)
- 616   29.   Lengliné, E. *et al.* Basket clinical trial design for targeted therapies for cancer: a French  
617   National Authority for Health statement for health technology assessment. *Lancet Oncol* **22**,  
618   e430–e434 (2021).
- 619   30.   Subbiah, V. *et al.* Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma  
620   Cancers. *Cancer Discov* **10**, 657–663 (2020).
- 621   31.   Allegretti, M. *et al.* Tearing down the walls: FDA approves next generation sequencing (NGS)  
622   assays for actionable cancer genomic aberrations. *J. Exp. Clin. Cancer Res.* **37**, 47–3 (2018).
- 623   32.   Rusch, M. *et al.* Clinical cancer genomic profiling by three-platform sequencing of whole  
624   genome, whole exome and transcriptome. *Nature Communications* **9**, 3962–13 (2018).
- 625   33.   U.S. Food and Drug Administration. U.S. FDA 510(k) clearance K190661: Omics Core  
626   NantHealth. 1–182 (2019). Available at:  
627   [https://www.accessdata.fda.gov/cdrh\\_docs/reviews/K190661.pdf](https://www.accessdata.fda.gov/cdrh_docs/reviews/K190661.pdf). (Accessed: 22nd April  
628   2021)
- 629   34.   U.S. Food and Drug Administration. U.S. FDA 510(k) clearance K192073: Helix OpCo, LLC. 1–19  
630   (2021). Available at: [https://www.accessdata.fda.gov/cdrh\\_docs/pdf19/K192073.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf19/K192073.pdf).  
631   (Accessed: 22nd April 2021)
- 632   35.   Alspach, E. *et al.* MHC-II neoantigens shape tumour immunity and response to  
633   immunotherapy. *Nature* **574**, 696–701 (2019).
- 634   36.   Corthay, A., Lundin, K. U., Lørvik, K. B., Hofgaard, P. O. & Bogen, B. Secretion of Tumor-Specific  
635   Antigen by Myeloma Cells Is Required for Cancer Immunosurveillance by CD4+ T Cells. *Cancer*  
636   *Res.* **69**, 5901–5907 (2009).
- 637   37.   Henning, P. *et al.* The subcellular location of antigen expressed by adenoviral vectors modifies  
638   adaptive immunity but not dependency on cross-presenting dendritic cells. *Eur. J. Immunol.*  
639   **41**, 2185–2196 (2011).
- 640   38.   Sedlik, C. *et al.* Different immunogenicity but similar antitumor efficacy of two DNA vaccines  
641   coding for an antigen secreted in different membrane vesicle-associated forms. *J Extracell*  
642   *Vesicles* **3**, (2014).
- 643   39.   Mitchell, J. P., Court, J., Mason, M. D., Tabi, Z. & Clayton, A. Increased exosome production  
644   from tumour cell cultures using the Integra CELLine Culture System. *J. Immunol. Methods* **335**,  
645   98–105 (2008).
- 646

647 **METHODS**

648

649 **OVA-expressing B16 melanoma cell lines**

650 B16F10 (B16) melanoma cells (American Type Culture Collection, Manassas, VA,  
651 USA) were genetically modified by transduction with OVA-encoding lentivirus. Briefly,  
652 OVA-encoding DNA sequences were purchased from GenScript (Piscataway, NJ,  
653 USA). In one design, full-length OVA (UniProtKB P01012) was fused at the N-  
654 terminus to the signal peptide of mouse H-2K<sup>B</sup> (aa1-aa21, UniProtKB P01901) and at  
655 the C-terminus to the transmembrane domain of mouse H-2D<sup>B</sup> (aa299-aa331,  
656 UniProtKB P01899). Sequences were subcloned in the pLV-mCherry backbone  
657 (Addgene #36804) in place of mCherry. Lentiviruses were made by polyethylenimine  
658 (PEI)-mediated transfection of human embryonic kidney (HEK) 293-T cells using  
659 OVA-encoding plasmid with the packaging plasmids pMD2.G (Addgene #12259),  
660 pMDLg/pRRE (Addgene #12251) and pRSV-Rev (Addgene #12253). Twelve hours  
661 after transfection, the cell culture medium was refreshed and 36 h later, the medium  
662 was collected and filtered at 0.22 µm. Lentiviruses were concentrated by  
663 ultracentrifugation at 100,000 xg for 2 h at 4°C and resuspended in phosphate-  
664 buffered saline (PBS). B16 cells cultured in 48-well plates were transduced by adding  
665 OVA-encoding lentiviruses in the culture medium and centrifuging at 1150 xg for  
666 30 min at room temperature, and then were cultured for 24 h, after which the medium  
667 was refreshed. For B16mOVA<sup>HI/LO</sup> and B16-OVA<sup>HI</sup>, monoclonal selection was  
668 performed by limiting dilution, and OVA-expression was quantified by quantitative  
669 polymerase chain-reaction (qPCR). The B16-OVA<sup>LO</sup> cell line was a gift from B. Huard  
670 (University of Geneva, Switzerland). All cell lines were tested as negative for  
671 mycoplasma contamination by PCR.

672

673

## 674 **Quantitative PCR for OVA expression**

675 Expression of OVA in B16 cell lines or tumors was quantified by qPCR. Prior to RNA  
676 extraction, 30-50 mg of tumor tissues were homogenized (FastPrep-24 5G, MP  
677 Biomedicals, Santa Ana, CA, USA) in RLT lysis buffer (Qiagen, Hilden, Germany),  
678 spun down at 10,000 xg for 10 min and the supernatant was collected. For cells in  
679 culture, 1-2 million cells were pelleted, washed with PBS and lysed in RLT buffer.  
680 RNA was extracted using the RNeasy Plus Mini kit (Qiagen). The extracted RNA (1  
681 µg) was then converted to cDNA using SuperScript IV VILO Master Mix  
682 (ThermoFisher Scientific, Waltham, MA, USA). All kits were used according to  
683 manufacturers instructions. TaqMan qPCR were finally performed using TaqMan  
684 Universal PCR Master Mix, OVAL primer (Gg03366807\_m1) and ActB primer  
685 (Mm02619580\_g1) (ThermoFisher Scientific), in a LightCycler 96 real-time PCR  
686 system (Roche Life Science, Basel, Switzerland).

687

## 688 **Detection of membrane-bound OVA**

689 Surface-expression of OVA was verified by flow cytometry and microscopy. Single  
690 cell suspensions of the different OVA-expressing B16 were incubated for 30 min on  
691 ice with anti-OVA (ab181688, Abcam, Cambridge, UK) in PBS + 2% fetal bovine  
692 serum (FBS). Cells were washed twice and stained using an anti-rabbit secondary  
693 antibody (A315723, Invitrogen, Carlsbad, CA, USA) for 20 min on ice in the dark.  
694 Cells were washed and analyzed by flow cytometry (BD LSRFortessa, BD  
695 Biosciences, Franklin Lakes, NJ, USA) or imaged by fluorescence microscopy (Leica  
696 DMI8, Wetzlar, Germany). Flow cytometry data were analyzed using FlowJo (FlowJo  
697 LLC) and microscopy images were processed using Fiji (ImageJ, U.S. National  
698 Institutes of Health, Bethesda, MD, USA).

699

700

## 701 **Extracellular vesicles (EV) isolation**

702 EV from the B16mOVA<sup>HI</sup> and B16-OVA<sup>HI</sup> cell lines were harvested using the  
703 CLAD1000 system (2440655, Cole-Parmer, Vernon Hills, IL, USA) as described by  
704 Mitchell *et al.* <sup>39</sup>. Briefly, 16 million cells were suspended in 15 mL complete EV-  
705 depleted DMEM (DMEM + 1% penicillin/streptomycin (P/S) + 10% exosome-depleted  
706 FBS (A2720801, Thermo Fisher Scientific)) and loaded into the lower chamber of the  
707 CLAD flask. The upper chamber was then loaded with DMEM + 1% P/S, and cells  
708 were allowed to recover for 4 days. On the 4th day, the upper reservoir was emptied  
709 and the media in the lower chamber was collected. The lower chamber was washed  
710 twice with DMEM, collecting only the first wash. The lower chamber was then refilled  
711 with 15 mL of complete EV-depleted DMEM. This harvesting process was repeated  
712 every 4 days. Collected media was first spun at 300 xg for 10 min to remove cells,  
713 then centrifuged at 3000 xg for 10 min to remove large cell debris and finally at  
714 10,000 xg for 30 min to further remove debris. The final supernatant was  
715 concentrated using 100,000 MWCO concentrator tubes (UFC910024, EMD Millipore,  
716 Burlington, MA, USA) before processing via size exclusion. Size exclusion was  
717 performed using the Izon qEV10 system (IZON SP3) according to the manufacturer's  
718 instructions to collect separately the EV fractions, containing particulates of 70-1000  
719 nm in size, and the non-particulates non-EV fractions. Once purified, EV harvests  
720 were pooled and re-concentrated. Total protein content of the purified EV was  
721 quantified using a Micro BCA kit (Thermo Fisher) before storage at -20°C. Equal  
722 amount of proteins (34 µg) were loaded on SDS-PAGE gels for further analysis by  
723 western blot.

724

## 725 **Western blot analysis**

726 Samples were run on SDS-PAGE gels for 45 min at 140 V (Mini-PROTEAN gel  
727 system, Bio-Rad Laboratories, Hercules, CA, USA) in Laemmli loading buffer before

728 being transferred onto western blot membranes (Immobilon-P PVDF membrane,  
729 EMD Millipore; Mini Trans-Blot cell, Bio-Rad) for 1 h at 90 V. Membranes were  
730 blocked using 5% milk in PBS + 0.05% Tween-20 (PBST) overnight at 4°C under  
731 agitation and probed with anti-OVA (ab181688) for 4 h at room temperature.  
732 Membranes were washed in PBST thrice and incubated with a horseradish  
733 peroxidase (HRP)-conjugated anti-rabbit secondary antibody for 1 h at room  
734 temperature. Membranes were washed at least 3 times for 5 min in PBST, revealed  
735 using the Clarity Western ECL substrate (Bio-Rad) and imaged using a gel imaging  
736 system (Universal Hood III, Bio-Rad).

737

### 738 **Mice**

739 All animal experimentation was approved by the University of Chicago Institutional  
740 Animal Care and Use Committee in compliance with local ethical and procedural  
741 regulations. Mice were purchased from The Jackson Laboratory (Bar Harbor, ME,  
742 USA). Female C57BL/6J (No 000664) or female MuMt mice (B6.129S2-*Ighm*<sup>tm1Cgn</sup>/J,  
743 No 002288) were between 8-12 weeks old at the start of the experiments, with mice  
744 being aged-matched within an experiment. Act-mOVA mice (C57BL/6-Tg(CAG-  
745 OVAL)916Jen/J, No 005145) were bred in-house and female mice of 25-35 week old  
746 were used for experimentation. Mice were housed at the Animal Resources Center  
747 Facility at the University of Chicago, had water and food *ad libitum*, and were daily  
748 monitored for health care.

749

### 750 ***In vivo* antibodies**

751 All antibodies used *in vivo* were the InVivoMAb grade antibodies purchased from  
752 Bio X Cell (Lebanon, NH, USA). Antibodies used as immune checkpoint therapies  
753 were anti-PD-1 (clone 29F.1A12), anti-PD-L1 (clone 10F.9G2) and anti-CTLA-4



754 (clone 9H10). Antibodies used for immune cell depletion were anti-CD8 $\alpha$  (clone  
755 2.43), anti-CD4 (clone GK1.5), anti-NK1.1 (clone PK136), Isotype IgG2a (clone  
756 C1.18.4), Isotype IgG2b (clone LTF-2).

757

## 758 **Tumor injections**

759 Mice were anaesthetized by isoflurane inhalation and were injected intradermally with  
760 1.5 million of the different OVA-expressing or WT B16 cell lines. The tumor was  
761 measured using a digital caliper every 2 days, and tumor volume was calculated as  
762 follows: volume = length\*width\*height\*( $\pi/6$ ). Mice were euthanized if sick or when the  
763 tumor volume reached 1 cm<sup>3</sup>. When indicated, mice were treated with  
764 immunotherapy, i.e. anti-PD-1 (200  $\mu$ g) or the combination anti-PDL-1 + anti-CTLA-4  
765 (100  $\mu$ g each), once by intraperitoneal injection when the tumor volume was between  
766 20-50 mm<sup>3</sup> (day 5-8 post-tumor injection). When needed, 500  $\mu$ g of depletion  
767 antibodies (anti-CD8 $\alpha$ , anti-CD4, anti-NK1.1 or isotype control) were injected  
768 intraperitoneally 24 h after the checkpoint inhibitor therapy and repeated 7 days later.  
769 In the re-challenge experiments, 250k WT B16 cells were injected intradermally on  
770 the contralateral side on the mice 1 month after they cleared the primary tumor.

771

## 772 **Flow cytometry analysis of tumor**

773 Ten days after tumor injection, tumor were harvested on euthanised mice. Tumors  
774 were weighed, and about 300 mg were processed. Tumors were cut into small  
775 pieces, digested for 45 min in collagenase IV (1 mg/mL), DNase I (40  $\mu$ g/mL) in  
776 DMEM + 2% FBS + 1.2 mM CaCl<sub>2</sub> at 37°C under magnetic stirring. The samples  
777 were pipetted 100 times to dissociate tumor pieces, and single cell suspensions were  
778 obtained by using 70  $\mu$ m cell strainer. Cells were kept on ice. Undigested pieces  
779 were further mixed with collagenase D (3.3 mg/mL), DNase I (40  $\mu$ g/mL) in DMEM +

780 2% FBS + 1.2 mM CaCl<sub>2</sub> for 30 min at 37°C and collected as above. EDTA (5 mM)  
781 was added to the single cell suspension. The equivalent of 20 mg of tumor was used  
782 for staining for flow cytometry analysis. Tumor samples were washed in PBS and  
783 stained for cell viability for 15 min using Fixable Viability Dye eFluor 455UV  
784 (eBioscience, San Diego, CA, USA). The cells were washed and Fc receptors were  
785 blocked using anti-CD16/32 (#101302, BioLegend) for 20 min. Cells were then  
786 stained for 20 min on ice using the following antibodies: anti-CD45 (30-F11), anti-  
787 CD8α (53-6.7), anti-PD-1 (29F.1A12), anti-NK1.1 (PK136), anti-Ly6G (1A8), anti-  
788 Ly6C (HK1.4), anti-CD11b (M1/70), anti-F4/80 (BM8), anti-I-A/I-E (M5/114.15.2),  
789 from BioLegend (San Diego, CA, USA); anti-CD3ε (145-2C11), anti-CD4 (GK1.5),  
790 anti-CD62L (MEL-14), anti-CTLA-4 (UC10-4F10-11), anti-CD25 (PC61), anti-CD80  
791 (16-10A1), anti-B220 (RA3-6B2), anti-CD19 (1D3), anti-CD11c (HL3), from BD  
792 Biosciences; anti-CD44 (IM7), anti-CD103 (2E7), from eBioscience. Cells were  
793 washed before analysis. When needed, intracellular staining with anti-FoxP3 (MF23,  
794 BD Biosciences) was performed using the BD Cytotfix/Cytoperm Plus kit (BD  
795 Biosciences) according to the manufacturer's instruction. All staining procedures  
796 were done on ice with samples protected from light, in PBS + 2% FBS + 1 mM EDTA  
797 when not stated otherwise. Cells were analyzed using a LSRFortessa flow cytometer  
798 (BD Biosciences). Data were processed using FlowJo (FlowJo LLC). Gating  
799 strategies for the flow analysis and biomarkers used to define cell populations are  
800 detailed in Supplementary Data 1.

801

### 802 ***Ex vivo* antigen-specific T cell restimulation**

803 Ten days after tumor injection, spleens were harvested on euthanized mice. Single  
804 cell suspensions of splenocytes were obtained using a 70 µm cell strainer. Cells  
805 were washed in PBS before the red blood cells were lysed in ACK buffer (Lonza,  
806 Basel, Switzerland) for 4 min and blocked with complete media (IMDM + 10% FBS +

807 1% P/S). Cells were centrifuged, resuspended in complete media, and 0.5 million  
808 were plated in in 96 U-bottom plate. OVA<sub>257-264</sub> (SIINFEKL; GenScript) and OVA<sub>323-339</sub>  
809 (ISQAVHAAHAEINEAGR; GenScript) were added to the splenocytes at a final  
810 concentration of 1 µg/mL to restimulate CD8<sup>+</sup> and CD4<sup>+</sup> T cells, respectively.  
811 Unstimulated controls were tested using complete media without peptide, and  
812 positive controls were tested using ionomycin (1 µg/mL) + PMA (50 ng/mL). After  
813 4 days in culture, the cell supernatant was collected and the amount of IFN $\gamma$  secreted  
814 was quantified using mouse IFN $\gamma$  quantikine ELISA kit (R&D systems, Minneapolis,  
815 MN, USA) according to the manufacturer's instructions. Data represent the  
816 concentration of IFN $\gamma$  secreted in restimulated culture supernatants subtracted with  
817 the amount detected in unstimulated supernatants.

818

819

## 820 **IgG titration in plasma**

821 Ten days after tumor injection, mice were bled by intracardiac puncture upon  
822 euthanasia. The blood was collected in EDTA-containing tubes, spun down at  
823 1000 xg for 5 min and the plasma was collected and stored at -80°C until analysis.  
824 ELISA plates (Maxisorp, Nunc, Roskilde, Denmark) were coated with 10 µg/mL OVA  
825 (Sigma-Aldrich, St. Louis, MO, USA) in PBS overnight at 4°C, and blocked with  
826 casein (Sigma-Aldrich, St. Louis, MO, USA) for 2 h at room temperature. The plates  
827 were washed with PBST, and plasma diluted in casein was added to the wells,  
828 starting at a concentration of 1:100 and serially diluted by 10, for 2 h at room  
829 temperature. The plates were washed again, and the following HRP-conjugated  
830 antibodies were used for detection: anti-mouse IgG1 (#1070-05), anti-mouse IgG2a  
831 (#1080-05), anti-mouse IgG2b (#1090-05) and anti-mouse IgG3 (#1100-05) from  
832 Southern Biotech (Birmingham, AL, USA). The plates were revealed with TMB  
833 substrate (EMD Millipore) and stopped with 2N H<sub>2</sub>SO<sub>4</sub>. Absorbance at 450 nm was

834 read using an Epoch ELISA reader (BioTek, Winooski, VT, USA), and corrected by  
835 the absorbance at 570 nm. Antibody titers were determined as the highest plasma  
836 dilution for which the corrected absorbance was twice the background level. The area  
837 under curve (AUC) was calculated as area under the titration curve of the  
838  $\log_{10}$ (corrected absorbance over background).

839

#### 840 **Human data analysis**

841 Processed sequencing data of tumor mutations (list of tumor mutated genes and  
842 tumor mutational burden score) and corresponding patient clinical data were  
843 obtained from the studies by Samstein *et al.*<sup>7</sup>, Hellman *et al.*<sup>8</sup>, and Hugo *et al.*<sup>9</sup>.  
844 Subcellular locations associated with *Homo Sapiens* genes (taxon ID = 9606) were  
845 uploaded from UniProtKB/Swiss-Prot database on August 2, 2020 and are provided  
846 in Supplementary Data 2 (Gene subcellular locations inventory). Algorithms for data  
847 processing and analysis were coded in R (Rstudio, Boston, MA, USA).

848 For each distinct tumor mutated gene of a patient, we searched the gene name that  
849 matches in the gene subcellular locations inventory file. Genes that were not found  
850 were categorized as "Unfound genes". Genes that were found but for which the  
851 subcellular location was unfound were further checked on the online  
852 UniprotKB/Swiss-Prot database using the `GetSubcellular_location()` function from the  
853 R package 'UniprotR'. If the gene subcellular location remained unfound, it was then  
854 categorized as "Unknown location". When multiple locations were found for a specific  
855 gene name, they were concatenated to obtain a single subcellular location entry per  
856 gene name. The gene subcellular locations were then categorized as membrane,  
857 cytoplasmic, nuclear or secreted by checking the presence of the character  
858 sequence: membrane = "Membrane" or "Cell membrane", cytoplasmic =  
859 "Cytoplasm", nuclear = "Nucleus", secreted = "Secreted" in the subcellular location

860 entry associated with the gene. When indicated, the categories were extended to the  
861 cell membrane = "Cell membrane", the endoplasmic reticulum = "Reticulum" or  
862 "reticulum", the Golgi apparatus = "Golgi" or "golgi", or endosomal location =  
863 "Endosome" or "endosome" or "Endosomal" or "endosomal". Oftentimes, a single  
864 gene name was associated with several subcellular locations, in which case the gene  
865 was included in several category in a non-exclusive way. For each patient, we  
866 counted the number of mutated genes at each specific subcellular locations, and the  
867 proportion of mutated genes at a specific location was computed as the "number of  
868 tumor mutated genes at a location divided by the total number of tumor mutated  
869 genes in the patient". Patients with no tumor mutated genes were removed from the  
870 analysis. In the presented data, groups of patients were determined using inclusive  
871 percentiles, except in groups separated at the median, for which the group below  
872 median was inclusive and the group above median was exclusive. In Fig. 5, "mTMB  
873 High" and "mTMB Low" correspond to groups of patients for which mTMB was  
874 respectively higher and lower than the median.

875 In R, survival analysis were performed using the libraries 'survival', 'survminer' and  
876 'survcomp' and the functions `survfit()` and `surv_pvalue()`. Hazard ratios were  
877 computed using the function `hazard.ratio()`. All these functions were used using log-  
878 rank tests when asked. In case of multiple comparisons, p-values were adjusted  
879 using the function `p.adjust()`.

880

### 881 **Analysis of the membrane-localized biomarkers**

882 HR of survival was computed for each membrane protein-encoding gene, between  
883 patients that bear mutated version of the gene vs. patients that bear the wild-type  
884 version of the gene. The analysis was done independently for each cancer type.  
885 Results were considered relevant to report (in Fig. 5) when at least 7 patients with a

886 mutated version of a gene were available, and 1) when the HR was  $\leq 0.5$  or  
887 statistically significance by the log-rank test was reached, or 2) when the HR ratio  
888 was  $\geq 1.3$  and close to statistically significance (p-value  $< 0.2$ ). The non ICI-treated  
889 cohort results were reported when at least 7 patients had the mutated version of the  
890 gene of interest.

891

## 892 **Statistics & Software**

893 Graphs were plotted using Prism 9 (GraphPad, San Diego, CA, USA). Statistical  
894 analysis were run on Prism 9 or on R (RStudio). Overall threshold for statistical  
895 significance was considered as p-value  $< 0.05$ . Figures were made on Illustrator CS5  
896 (Adobe, San Jose, CA, USA).

897

## 898 **Material, data and code availability**

899 Tumor mutation sequencing data for the human cohorts used in this study are  
900 publicly available from Samstein *et al.*<sup>7</sup>, Hellman *et al.*<sup>8</sup> and Hugo *et al.*<sup>9</sup>. Subcellular  
901 locations associated to *Homo Sapiens* genes are provided in Supplementary Data 1  
902 and updated versions can be downloaded from the UniProtKB/Swiss-Prot database.  
903 Proportion of mutation subcellular locations per patient and corresponding selected  
904 clinical data are provided in Supplementary Data 2-5. Other material, data and code  
905 remains available upon request to the corresponding authors.

906

907

908

909

910

911

912 **SUPPLEMENTARY INFORMATION**

913

914 **Supplementary Data 1:** Subcellular locations of proteins associated with *Homo*  
915 *Sapiens* genes.

916 **Supplementary Data 2:** Proportion of mutations at specific location for ICI-treated  
917 cohort from Samstein *et al.*<sup>7</sup>

918 **Supplementary Data 3:** Proportion of mutations at specific location for the non-ICI-  
919 treated cohort from Samstein *et al.*<sup>7</sup>

920 **Supplementary Data 4:** Proportion of mutations at specific location for the NSCLC  
921 patients cohort from Hellman *et al.*<sup>8</sup>

922 **Supplementary Data 5:** Proportion of mutations at specific location for the  
923 melanoma patients cohort from Hugo *et al.*<sup>9</sup>

924 **Supplementary Data 6:** HR of survival per mutated genes and per cancer type for  
925 the ICI and non-ICI treated patients cohort from Samstein *et al.*<sup>7</sup>

926

927

928 **ACKNOWLEDGMENTS**

929

930 The authors would like to thank Prof. Luc G. T. Morris and Prof. David B. Solit for  
931 their help in the use of their clinical dataset, Dr. Raga Krishnakumar, Dr. Alexandre  
932 de Titta and Dr. Sandra Gribi for advice on data analysis and Dr. Jialu Liu for  
933 technical assistance. This article is dedicated to the memory of Anthony Gomes. This  
934 work was funded by the Chicago Immunoengineering Innovation Center of the  
935 University of Chicago and NIH R01 CA219304 (to M.A.S.).

936



937

## 938 **AUTHOR CONTRIBUTIONS**

939

940 P.S.B., S.H., M.A.S. and J.A.H. have conceived the project and designed the  
941 experiments. P.S.B., S.H., Z.G., T.K., A.T.A., G.R., Y.W. and S.G., performed the  
942 experiments. P.S.B., S.H., Z.G., T.K, P.B and J.A.H. analyzed and interpreted the  
943 data. P.S.B, J.A.H., and Z.G. wrote the manuscript, and S.H., P.B. and M.A.S.  
944 corrected it.

945

946

## 947 **COMPETING INTERESTS**

948

949 The University of Chicago has filed for patent protection for biomarkers described in  
950 this work, upon which P.S.B., Z.G., S.H. and J.A.H. are inventors. Other authors  
951 have no competing interest to declare.

952